FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Off-Protocol Radiotherapy in Prospective Systemic Therapy Trials for Metastatic Non-Small Cell Lung Cancer. PMID 42314501 · Clin Lung Cancer · 2026-Jul The record is a methodological review/meta-analysis of systemic therapy trial protocols, not an original report of trial results. It does not present any primary or secondary time-to-event efficacy data (e.g., OS, PFS, Kaplan-Meier curves, HR) from a randomized trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma. PMID 42293288 · JTO Clin Res Rep · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study. PMID 42275799 · ESMO Open · 2026-Jul The study is a randomized Phase IV trial, which does not meet the inclusion criterion for Phase III/IIIb or Phase II/III trials. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. PMID 42269655 · Lancet Oncol · 2026-Jul The trial is a Phase 3 randomized controlled trial in prostate cancer with original results, but the intervention is a diagnostic imaging agent ([68Ga]Ga-PSMA-11 PET-CT) and the primary endpoints are diagnostic accuracy and biopsy avoidance, not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004. PMID 42258989 · Gynecol Oncol · 2026-Jul The record describes a psychometric evaluation of patient-reported outcome measures (quality-of-life instruments) from a Phase III randomized trial in oncology. While it originates from an eligible trial type, the report itself is a secondary, quality-of-life analysis focusing on instrument validation, not a report of the trial's primary or key secondary time-to-event efficacy results (e.g., OS, PFS). Therefore, it is excluded as a quality-of-life-only report. |
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Progression-free Survival Following Primary Staging with [18F]PSMA-1007-PET/ceCT Versus Na[18F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial. PMID 42255253 · Eur Urol Open Sci · 2026-Jul The study is a randomized oncology trial with PFS as a primary endpoint, but it lacks a drug-containing intervention (comparing imaging tracers) and does not explicitly state the trial phase as Phase III or definitive. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease. PMID 42226468 · J Dermatol · 2026-Jul The study is a safety analysis of a drug (guselkumab) in psoriatic disease, not a human malignant neoplasm (oncology) trial. It reports on safety outcomes (TB reactivation, liver enzyme elevations) and does not include a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curve, or hazard ratio for such outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Secondary Analysis of the CAN-Study, a Randomised Controlled Trial - Local Anaesthesia and Overall Survival. PMID 42210709 · Acta Anaesthesiol Scand · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249. PMID 42190623 · Gynecol Oncol · 2026-Jul The report is an ancillary biomarker analysis of a randomized trial. While it meets many criteria (oncology, human, randomized, drug intervention, time-to-event endpoints), the specific requirement for an original formal result report of a Phase III/IIIb or Phase II/III trial with a drug intervention is not met. The phase is not explicitly established in the provided text, and the report's primary focus is prognostic biomarker classification rather than the primary efficacy comparison of the drug intervention vs. control. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The CHRONO trial: Protocol for a randomized controlled trial of early time-restricted eating in patients with breast or rectal cancer. PMID 42190452 · Nutr Res · 2026-Jul 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial. PMID 42175630 · J Gastroenterol Hepatol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials. PMID 42172953 · Int J Gynecol Cancer · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-term oncological and reproductive outcomes following treatment with the levonorgestrel intra-uterine device for endometrial hyperplasia and adenocarcinoma: results from the feMMe phase 2 randomized clinical trial. PMID 42167104 · Int J Gynecol Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Fosfomycin versus ciprofloxacin for febrile neutropenia prophylaxis in high-risk haematological patients (FOVOCIP): a phase 3, open-label, multicentre, randomised, non-inferiority trial. PMID 42164340 · Lancet Reg Health Eur · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Multimodal prehabilitation in patients with advanced ovarian cancer. PMID 42155563 · Gynecol Oncol · 2026-Jul The trial is oncology-focused, human, and randomized, but it does not meet all required criteria: the phase is not specified as Phase III or IIIb, the intervention is multimodal prehabilitation (non-drug), and the primary endpoint is functional capacity (6MWT), not a time-to-event efficacy endpoint (OS, PFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of comprehensive geriatric assessment and supportive care on quality of life in older patients with cancer receiving curative treatment: The GOSPEL randomised controlled trial. PMID 42155314 · J Geriatr Oncol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| [Oligometastatic hormone-sensitive prostate cancer: when can less be more?]. PMID 42151597 · Urologie · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Response to the letter to the editor by Pontoriero et al. regarding the article "Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international randomised phase 3 trial by Van den Heerik et al.". PMID 42128303 · Radiother Oncol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Biopsy with same-session MRI-guided laser interstitial thermal therapy versus biopsy alone in patients with primary unresectable glioblastoma: a multicentre randomised controlled trial. PMID 42112495 · Lancet Reg Health Eur · 2026-Jul The record is a randomized trial for human glioblastoma with an OS endpoint, but the intervention is a procedure (LITT) and not a drug, and the phase is not established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer. PMID 42103553 · Lung Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study. PMID 42098463 · Int J Clin Oncol · 2026-Jul The study meets the criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it fails the core requirement for a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The reported endpoints are pharmacokinetic, pathological complete response, and safety. Therefore, it is not eligible for inclusion in this cohort. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Integrated perioperative host-response optimization improves functional recovery and survival after ultra-low anterior resection: A randomized controlled trial. PMID 42092267 · Surgery · 2026-Jul The trial is a randomized, oncology-focused study with time-to-event endpoints, but the intervention is a non-drug perioperative optimization program, which violates the drug-intervention requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study. PMID 42067068 · Radiother Oncol · 2026-Jul The study meets criteria for oncology, human, randomized, and Phase III, but is excluded because it lacks a drug-containing intervention (intervention is radiotherapy) and lacks a time-to-event efficacy endpoint (endpoint is patient-reported arm swelling, a safety/toxicity outcome). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL). PMID 42059487 · Palliat Med · 2026-Jul The study is a randomized Phase III oncology trial with a drug intervention, but its primary and reported endpoints are quality of life, body weight, and cost parameters. There is no signal of a time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier) in the title, abstract, or metadata. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. PMID 42044466 · J Clin Oncol · 2026-Jul This record describes a secondary, correlative analysis of circulating tumor DNA (ctDNA) from the TRANSFORM trial, not the primary efficacy report. While the trial itself is likely a randomized Phase III study (as it compares a new therapy to standard of care in a second-line setting), the provided text is a biomarker-focused analysis ('correlative circulating tumor DNA analyses'). The eligibility criteria require the 'original formal-result report' of the primary/key secondary time-to-event endpoint. This report's primary purpose is to present ctDNA biomarker associations, making it a secondary or correlative analysis report, not the primary efficacy report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The ALLAN trial: impact of early home-based palliative care on emergency care and hospitalisation in advanced gastrointestinal cancer patients. PMID 42032200 · Br J Cancer · 2026-Jul The trial is a randomized controlled trial in advanced gastrointestinal cancer patients with a drug-containing intervention (palliative chemotherapy), but it does not meet the key eligibility criteria. The primary endpoint is quality of life, and the presented results focus on secondary outcomes (healthcare utilization, place of death). There is no primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) reported; the only time-related outcome ('time from last chemotherapy to death') is not presented with KM data or HR and is described as not significantly different. The report is not a Phase III/IIIb or definitive Phase II/III trial (phase is not established in the provided metadata). It is a secondary analysis of a trial focused on palliative care integration, not a definitive drug efficacy report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic extrahepatic Glissonian versus hilar dissection approach for major hepatectomy in patients with HCC: a randomized controlled trial. PMID 42020776 · Br J Cancer · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial. PMID 42014556 · Br J Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer. PMID 42005715 · Clin Transl Radiat Oncol · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. PMID 41999030 · J Hepatobiliary Pancreat Sci · 2026-Jul The record describes an ancillary analysis of the JASPAC 01 trial, not the original formal result report of the Phase III trial. The analysis evaluates the timing of adjuvant chemotherapy initiation (early, standard, delayed) rather than the trial's primary comparison of S-1 vs. gemcitabine. The phase is not explicitly confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7. PMID 41975042 · Br J Cancer · 2026-Jul While the record describes a Phase III randomized trial (DREAMM-7) with a drug intervention, the abstract focuses on pharmacometric exposure-response modeling for response (e.g., ≥VGPR) and safety endpoints. There is no mention of a time-to-event efficacy endpoint (e.g., OS, PFS) or associated Kaplan-Meier/HR results. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Minimizing Early-Onset Lymphedema Following Groin Dissection in Metastatic Melanoma. PMID 41973292 · Ann Surg Oncol · 2026-Jul The study is a randomized oncology trial but does not meet key eligibility criteria: it lacks a drug-containing intervention (uses compression garments and lymphatic drainage), does not report a time-to-event efficacy endpoint as a primary/key secondary (primary endpoint is 24-month incidence, a proportion), and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative Biliary Drainage with Metal Stent Versus Early Surgery in Patients with Pancreatic Cancer: A Randomized Clinical Trial. PMID 41951900 · Ann Surg Oncol · 2026-Jul 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Motivation-informed digital reminders were no more effective than standard reminders for trial task completion in a randomized Study Within A Trial (SWAT). PMID 41933841 · J Clin Epidemiol · 2026-Jul The record is an original randomized trial on melanoma (oncology), but it is a 'Study Within A Trial' (SWAT) evaluating the effectiveness of digital reminder systems for trial task completion. It does not involve a drug intervention, nor does it report a time-to-event efficacy endpoint (OS, PFS, etc.) from a Phase III/IIIb or Phase II/III randomized trial of a cancer drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. PMID 41894094 · Int J Hematol · 2026-Jul The record is a primary result report of a Phase III randomized trial in human oncology with a drug intervention and a time-to-event efficacy endpoint (PFS with HR). All required criteria are explicitly established in the title, abstract, and metadata. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 1 Panel · risk visible |
| Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials. PMID 41887529 · JHEP Rep · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026;89:437-445. PMID 41864760 · Eur Urol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Topical honey as adjunctive therapy to standard dressing in deep neck abscess: a single-blind randomized controlled trial. PMID 41841442 · Acta Otolaryngol · 2026-Jul The study is a randomized controlled trial in humans with original results, but it is excluded because it is not an oncology study, does not involve a drug intervention, is not a Phase III/definitive trial, and does not have a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Value of NBI in the Detection of Local Recurrences of Head and Neck Squamous Cell Carcinoma After (Chemo)radiotherapy: A Randomised Controlled Trial. PMID 41821153 · Clin Otolaryngol · 2026-Jul The study is a randomized controlled trial in oncology (HNSCC) with survival endpoints, but it does not involve a drug-containing intervention. The intervention is diagnostic (NBI vs. WLI endoscopy), not a therapeutic drug. Therefore, it fails the required drug-intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Results of a Randomized Phase 2 Trial of One Versus Two 8 Gy Fractions for Painful Bone Metastases. PMID 41812711 · J Pain Symptom Manage · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II). PMID 41763980 · Int J Gynecol Cancer · 2026-Jul Protocol for a Phase III randomized trial in human oncology (ovarian cancer) but lacks a drug-containing intervention (evaluates surgical technique), is not yet reporting results, and does not have a time-to-event primary endpoint (evaluates diagnostic accuracy). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. PMID 41748387 · Eur Urol · 2026-Jul Eligibility cannot be determined because the record lacks explicit time-to-event endpoint signals and sufficient information about the original formal results and human subject status. Set is_eligible to null. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial. PMID 41577503 · Int J Gynecol Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of a Volunteer-Led Precision-Medicine Multilevel Intervention on Patient-Reported Outcomes, Receipt of Biomarker Testing, and Time to Treatment: A Randomized Clinical Trial. PMID 40953357 · JCO Oncol Pract · 2026-Jul The study is a randomized trial in oncology (non-small cell lung cancer) with human participants, but it does not meet key eligibility criteria: 1) The intervention is non-drug (volunteer-led education/alert system). 2) The primary/secondary outcomes are patient-reported outcomes (knowledge, activation, satisfaction), a process measure (molecular testing rate), and time to treatment, none of which are time-to-event efficacy endpoints like OS, PFS, DFS, etc. 3) The trial phase is not specified as Phase II/III or Phase III/IIIb in the provided metadata, and cannot be inferred. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| How Sticky Are Clinical Trial Interventions? Site-Level Clinical Trial Participation and Differential Post-Trial Use of a Genomic Test. PMID 40934443 · JCO Oncol Pract · 2026-Jul The record describes an implementation study analyzing the effect of trial participation on post-trial use of a genomic classifier in prostate cancer. It is not a drug-intervention trial, does not report a primary time-to-event efficacy endpoint (like OS/PFS), and does not meet the Phase III requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial. PMID 40854168 · JCO Oncol Pract · 2026-Jul The trial is a randomized controlled trial in oncology patients and reports original results including an OS endpoint. However, it is ineligible because the intervention is non-drug (eHealth platform) and the primary endpoint is quality-of-life, not the time-to-event endpoint required. The phase is also not explicitly confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of pleural lavage fluid volume on perioperative outcomes in non-small cell lung cancer patients undergoing video-assisted thoracoscopic lobectomy: a randomized controlled trial. PMID 41659268 · Transl Lung Cancer Res · 2026-Jan-31 The study is a randomized controlled trial in non-small cell lung cancer, but it evaluates a procedural intervention (pleural lavage volume) with no drug intervention. The primary and secondary outcomes (fever rates, complications, hospital stay) are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, RFS, TTP) and do not involve Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Testing the effects of segmented crowdsource-selected messages to improve intentions to follow colorectal cancer screening recommendations: study protocol for a randomized controlled trial. PMID 41620698 · BMC Public Health · 2026-Jan-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. PMID 41618415 · Trials · 2026-Jan-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Construction and application of an ERAS-based nursing pathway for postoperative pain management in brain tumor patients. PMID 41618043 · J Neurooncol · 2026-Jan-30 The study is a randomized trial in oncology (brain tumor surgery) with human subjects and reports original results, but it does not meet key eligibility criteria. It is not a Phase III/IIIb or definitive Phase II/III trial (phase is not specified). The intervention is a non-drug nursing pathway (ERAS-based), not a drug-containing intervention. The primary endpoints are pain scores, analgesic consumption, recovery metrics, and satisfaction; none are time-to-event efficacy endpoints like OS, PFS, DFS, EFS, RFS, or TTP, and there is no mention of Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |